ExcelMab Inc. announced that it has recently completed a RMB 100 million pre-B round of financing, which is mainly used for the clinical studies of two BsAb drugs——EX101 and EX103, and to accelerate the IND filing of the subsequent pipelines. This round of financing was led by Tatai Capital, followed by Guangzhou Huangpu Biomedical Investment, Guangzhou Development Zone Fund and Fijun Yongping Capital, with Taihe Capital acting as the exclusive financial advisor.

Dr. Wenjun Zhang, Founder and Chairman of ExcelMab, said, "We thank our investors for their recognition. In the coming time, ExcelMab's self-developed bispecific antibody drugs will enter the global clinical development stage. Meanwhile, our strong capability of new drug development has been increasingly highlighted and will enter the high-speed growth period of corporate development. "

Deng Ying, medical partner of Datai Capital, said: Against the background of the global innovation wave, bispecific antibodies are gradually emerging, and the launch of Removab®, Blincyto®, Hemlibra®, Rybrevant® and other drugs marks the official opening of the bispecific antibody era. Under the leadership of its founder, Dr. Wenjun Zhang, ExcelMab has established a series of BsAb R&D platforms represented by ExMab®, and the company will enter a period of rapid development as several dual antibodies move towards the clinical stage. We believe that Dr. Zhang's past successful experience in the development of bispecific antibodies and his team's rich experience in the field of biologics will be an important guarantee for the steady development of Esmeralda in the future.

At present, several bispecific antibodies developed by ExcelMab are in the process of initiating clinical studies in China and the U.S., aiming to obtain the recognition of breakthrough therapies as soon as possible.

EX103, the first CD20×CD3 bispecific antibody developed independently in China, has entered the phase I clinical study. EX103 has demonstrated a much higher safety profile than similar molecules in development in preclinical studies, and will be launched in international multi-center clinical trials, and is expected to become the world's best same-target molecule.

EX101, a new generation of HER2×CD3 bispecific antibody, has also entered the clinical preparation stage, and its preclinical data has demonstrated potent anti-tumor effects and excellent safety.

Based on its self-developed high-efficiency antibody discovery platform and BsAb platform ExMab®, ExcelMab has developed several new drug pipelines for different targets and indications, such as EX104/EX105, which have demonstrated excellent anti-tumor effects in preliminary studies and are progressing steadily as planned, with simultaneous IND filings expected in 2022. IND filings are expected to be made simultaneously in the U.S. and China.

In order to further advance the subsequent product development and international multi-center studies for each pipeline, ExcelMab will initiate a Series B financing in 2022.